iannisaifantis1 Profile Banner
Iannis Aifantis Profile
Iannis Aifantis

@iannisaifantis1

Followers
10K
Following
29K
Media
521
Statuses
5K

Cancer & Immunology Research. Professor & Chair, @NYUGSOM_Path @nyugrossman. All opinions are my own only. Visit me also on @instagram and @LinkedIn.

New York City, NY
Joined October 2015
Don't wanna be here? Send us removal request.
@iannisaifantis1
Iannis Aifantis
5 months
Excited to share with all our latest work on the use of single cell tools in following IDH mutant AML patients during their treatment! Out today @CellStemCell !! An amazing collaboration with @AkEisfeld & @PapaemmanuilLab & @landau_lab !!! Driven by the impressive @MariaSirenko
13
59
248
@iannisaifantis1
Iannis Aifantis
1 day
A lot of fun to be in Athens for this great meeting! #hematology #leukemia #oncology
@_MDEducation
MD Education
2 days
More highlights from Day 1 of the AML-ALL EU Focus Meeting 2025 in Athens. Sign up to watch the full meeting recording: https://t.co/YJQzX5NdQY #Hematology #Oncology #AML #ALL #Leukemia @Daver_Leukemia @sanamloghavi @charliecraddock @cpapayannidis
1
1
22
@LeukDocJZ
Joshua Zeidner MD
1 day
Fantastic news for AML patients with the extended approval of Revumenib for R/R NPM1m AML! Congrats to all investigators & those on the frontlines! We are truly in a new era of targeted therapies for AML 👏👏👏
@OncBrothers
Oncology Brothers
2 days
Revumenib is now @US_FDA ✅ for R/R AML w/ NPM1 mutation (approved for KMT2A translocation previously). - ORR 46.9% - Response seen in all subgroups (comutations, previous HSCT, or high number of prior lines of Rx). #HemeTwitter @beatalleukemia @LeukDocJZ 👏👏
1
7
53
@PapapetrouMDPhD
Eirini Papapetrou, MD, PhD
2 days
Last day of @FEBSnews workshop on aging in hematopoiesis in beautiful Crete. So many inspiring talks! Great to meet colleagues and new young scientists. Inspiring science in the sun- what more can you wish for? Many thanks and congratulations to the organizers!
0
2
28
@JohnPLeonardMD
John P. Leonard, MD
2 days
Enjoying ⁦@BloodCancerUtd⁩ Light the Night with ⁦@nyulangone⁩ ⁦@Perlmutter_CC⁩ team!
0
4
22
@jane_skok
Jane Skok
3 days
The Skok Lab is recruiting an experienced computational scientist to lead single-molecule epigenomic and 3D genome analysis. We integrate long-read sequencing with Hi-C/Hi-ChIP, scmulti-omics, and machine-learning to explore chromatin topology, and gene regulation.
0
5
17
@adam_grippin
Adam Grippin
4 days
🚨Our new paper is out today in Nature! We show that SARS-CoV-2 mRNA vaccines can sensitize tumors to immune checkpoint blockade (ICI) — revealing that clinically available RNA vaccines may act as potent immune modulators.
Tweet card summary image
nature.com
Nature - mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to immune checkpoint inhibitors.
23
53
171
@MariaSirenko
Maria Sirenko
4 days
Inspired by last night’s ⁦@CancerResearch⁩ Institute gala and the amazing community dedicated to advancing cancer research. Honored to be a CRI Fellow! Thank you for your support! ✨
0
3
36
@iannisaifantis1
Iannis Aifantis
4 days
Join us on November 25th, online, to discuss 3D nuclear organization, gene transcription and human cancer! Organized by @jane_skok and @NYUGSOM_Path !!
0
5
19
@NYUGSOMpathres
NYUGSOM Pathology Residency
5 days
As the weather turns chilly and the leaves start to fall, our @nyugsom_path residents took to Queens County Farm Museum for a “Maze by Moonlight” Corn Maze activity! We found all the clues to finish the maze and learned some “Kernals of Knowledge” along the way too! Happy Fall!🎃
0
4
13
@iannisaifantis1
Iannis Aifantis
6 days
Excited to be this week at the "Aging and Hematopoiesis" workshop organized by @FEBSnews on the beautiful island of Crete in Greece! An amazing line up of speakers!
@FEBSnews
FEBS
3 months
Register today for the FEBS Workshop on Aging in Hematopoiesis that will take place in Crete on 20-24 October 2025. An outstanding scientific program in a beautiful location! More information: https://t.co/9kdAeJCWCf
1
2
28
@jane_skok
Jane Skok
9 days
Ever wondered how the 3D shape of DNA influences nucleosome spacing along chromatin? Dr. Vijay Ramani from the Gladstone Institute, will reveal fresh, unpublished insights on this topic, featuring a new method – LASSI – that tracks single-molecule sequence interactions in 3D.
0
4
20
@ASCOPost
The ASCO Post
8 days
🔍 New study from @ALLIANCE_org and AML Cooperative Group asks: Are age-based treatment classifications for #AML outdated? 🔻 5yr OS by age: 73% (ages 18–24) to 21% (≥75) @AkEisfeld suggests a shift toward biology-driven eligibility over age thresholds. https://t.co/WhEzFuj7Fl
1
7
7
@iannisaifantis1
Iannis Aifantis
10 days
Congratulations to one of the best physicians, scientists, collaborators and friends out there! Such a great choice for MSKCC!
@MSKCancerCenter
Memorial Sloan Kettering Cancer Center
10 days
Dr. Ross Levine (@rosslevinemd), Senior Vice President of Translational Research at MSK, has been named MSK's new Chief Scientific Officer (CSO). Dr. Levine will be responsible for setting and leading strategy for basic and translational research, including programs, centers,
0
1
59
@iannisaifantis1
Iannis Aifantis
10 days
Very cool study by @glytsou (with some help from our lab and @LabScorrano ) targeting OPA1 in AML and combining it with BH3 mimetic treatment! #drugresistance #leukemia #Venetoclax
@glytsou
Christina Glytsou
11 days
Big news from the #Glytsoulab today!✍️Our research on drug resistance in leukemia is published in @ScienceAdvances. Targeting OPA1 can help overcome therapy resistance in AML, including the most challenging cases. 📖
1
0
28
@DrShrutiNaik
Dr. Shruti Naik
12 days
A paper many years in the making across multiple labs and institutions! Transient skin inflammation can have profound influence in reprogramming immune responses globally! @AWeinstock @iannisaifantis1 #teamworkdreamwork
@iannisaifantis1
Iannis Aifantis
12 days
Out today the last piece of work that Maria Guillamot did in our lab in a collaboration with @AWeinstock and @DrShrutiNaik (who lead the study) showing type I interferon (IFN)-mediated activation of hematopoietic stem/progenitor cells resulting in profound changes to systemic
3
21
115
@AWeinstock
AdaWeinstock
12 days
Your immune system remembers skin inflammation long after it resolves because of #interferon alpha! Check out our new paper describing these findings just published at @J_Immunol 👇👇👇 https://t.co/RbLNEsIrAY
Tweet card summary image
academic.oup.com
Abstract. Inflammation has enduring impacts on organismal immunity. However, the precise mechanisms by which tissue-restricted inflammation conditions syst
@iannisaifantis1
Iannis Aifantis
12 days
Out today the last piece of work that Maria Guillamot did in our lab in a collaboration with @AWeinstock and @DrShrutiNaik (who lead the study) showing type I interferon (IFN)-mediated activation of hematopoietic stem/progenitor cells resulting in profound changes to systemic
4
6
43
@iannisaifantis1
Iannis Aifantis
12 days
Out today the last piece of work that Maria Guillamot did in our lab in a collaboration with @AWeinstock and @DrShrutiNaik (who lead the study) showing type I interferon (IFN)-mediated activation of hematopoietic stem/progenitor cells resulting in profound changes to systemic
4
27
142
@NobelPrize
The Nobel Prize
16 days
BREAKING NEWS The Norwegian Nobel Committee has decided to award the 2025 #NobelPeacePrize to Maria Corina Machado for her tireless work promoting democratic rights for the people of Venezuela and for her struggle to achieve a just and peaceful transition from dictatorship to
25K
54K
189K
@jane_skok
Jane Skok
18 days
Join @BiolaMJavierre as she unveils the first-ever gene regulatory roadmap of human B cell differentiation – linking chromatin architecture, enhancer activity, and disease risk across nine B cell subtypes. n
0
3
15
@_TanyaBondar_
Tanya Bondar
18 days
It has been a pleasure and honor working with @DrTonyLetai as @BCD_AACR Scientific Editor, and author of this 2024 article published simultaneously with his talk at the inaugural Blood Cancer Discovery Symposium:
Tweet card summary image
aacrjournals.org
AbstractIn many cancers, mortality is associated with the emergence of relapse with multidrug resistance (MDR). Thus far, the investigation of cancer relapse mechanisms has largely focused on...
@AACR
AACR
27 days
The AACR congratulates Anthony Letai, MD, PhD, on his appointment as the 18th Director of the National Cancer Institute. We look forward to working with Dr. Letai and the NCI to advance our shared mission to prevent and cure all cancers. https://t.co/CVERcaZ6cQ @theNCI
1
4
11